Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Yuki Matsui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4219-2437; OpenAlex author ID A5101929232. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 9

  1. Survival Impact of Pathological Residual Patterns for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1002/jhbp.70146↗
  2. Long-term outcomes of prophylactic right-half dissection of the superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic ductal adenocar… Co-author DOI 10.1007/s00595-025-03062-6↗
  3. Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-024-16361-y↗
  4. Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib. Co-author DOI 10.1186/s40792-024-01975-x↗
  5. Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail. Co-author DOI 10.1002/ags3.12608↗
  6. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal aden… Co-author DOI 10.1016/j.pan.2022.11.012↗
  7. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospectiv… Co-author DOI 10.21037/jgo-23-655↗
  8. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Co-author DOI 10.3390/cancers14051354↗
  9. Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With KRAS Mutation. Co-author DOI 10.21873/anticanres.14701↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. So Yamaki · 8 shared papers, 2022–2026 · strength 1.63
  2. Sohei Satoi · 8 shared papers, 2022–2026 · strength 1.63
  3. Daisuke Hashimoto · 8 shared papers, 2022–2026 · strength 1.63
  4. Tsukasa Ikeura · 5 shared papers, 2022–2025 · strength 0.89
  5. Mitsugu Sekimoto · 5 shared papers, 2022–2025 · strength 0.89
  6. Hidetaka Miyazaki · 3 shared papers, 2024–2026 · strength 0.72
  7. Tomohisa Yamamoto · 4 shared papers, 2022–2023 · strength 0.66
  8. Denys Tsybulskyi · 3 shared papers, 2023–2025 · strength 0.61
  9. Satoshi Hirooka · 2 shared papers, 2022–2023 · strength 0.32
  10. Hiroyuki Ishida · 1 shared paper, 2026 · strength 0.29
  11. Nobuhiko Nakagawa · 1 shared paper, 2025 · strength 0.25
  12. Tsutomu Fujii · 1 shared paper, 2025 · strength 0.25
  13. Masashi Kanai · 1 shared paper, 2025 · strength 0.22
  14. Takumi Funo · 1 shared paper, 2024 · strength 0.21
  15. Tatsuma Sakaguchi · 1 shared paper, 2023 · strength 0.17
  16. Koh Nakamaru · 1 shared paper, 2022 · strength 0.13
  17. Yukako Ιtο · 1 shared paper, 2020 · strength 0.11
  18. Yuzuru Ikehara · 1 shared paper, 2020 · strength 0.11
  19. Hayao Nakanishi · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.